A dramatic rally saw shares of telehealth company Hims & Hers Health, Inc. soar approximately 57% over the course of a single week, closing at $24.77 on Friday. This powerful upward move was fueled by two significant announcements: the resolution of a high-profile patent dispute and a strategic acquisition aimed at international expansion.
A Pivotal Partnership Replaces Litigation
In a major strategic pivot, Hims & Hers has settled its patent litigation with pharmaceutical giant Novo Nordisk. The conflict, which was pending at the start of the year, has not only been resolved but has transformed into a commercial partnership. As part of the agreement, Hims & Hers will cease marketing or selling any compounded GLP-1 medications. Instead, the platform will begin offering Novo Nordisk’s branded drugs, Ozempic and Wegovy, directly to its customers.
This marks a fundamental shift in the company’s approach to weight management treatment. While compounded drugs typically offer higher margins, the new strategy pivots to distributing established brand-name pharmaceuticals. Whether the potential loss in per-unit profitability can be offset by significantly higher sales volumes remains a key question for the business model.
Accelerating Global Footprint Through Acquisition
Concurrently, the company finalized its acquisition of Eucalyptus, an Australian-based digital health services provider. This transaction provides Hims & Hers with immediate operational access to the Australian and Japanese markets, effectively complementing its existing presence in the United Kingdom, Germany, and France.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Financial Outlook and Executive Compensation
Management has provided a revenue forecast for the full year 2026, projecting sales to land between $2.7 billion and $2.9 billion. This outlook follows a strong fiscal 2025 performance, where the company generated $2.35 billion in revenue—a substantial 59% increase over the prior year.
In a separate filing on March 13, the company disclosed new equity awards for two senior executives. Chief Policy Officer Deborah M. Autor was granted 526,711 Restricted Stock Units (RSUs), while Chief Legal Officer Soleil Boughton received 188,111 RSUs. Both grants are subject to a standard four-year vesting schedule commencing in mid-2026.
Market Valuation and Strategic Calculus
At its Friday closing price of $24.77, the equity trades about 7% above the average analyst price target of $23.12. The market’s positive reception clearly prices in the combined impact of the Novo Nordisk partnership and the Eucalyptus deal. The central investment thesis now hinges on whether contributions from accelerated international growth can adequately compensate for the lower margins inherent in branded drug distribution. Investors will likely look to the quarterly results for the first half of 2026 for an initial answer.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from March 15 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 15.
Hims & Hers: Buy or sell? Read more here...
